Posted by Michael Wonder on 17 Jul 2025
Enhertu plus pertuzumab granted breakthrough therapy designation in the US as first-line therapy for patients with HER2 positive metastatic breast cancer
17 July 2025 - Ninth breakthrough therapy designation for Daiichi Sankyo and AstraZeneca’s Enhertu with the latest based on DESTINY-Breast09 Phase 3 trial results.
Enhertu (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab has been granted breakthrough therapy designation in the US for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer.
